Intact or in Pieces? A Look at How Clinically Approved, Biodegradable Block Co-Polymers Affect Blood Components
Source abstract
Abstract
-glycolic) acid) (PEG-PLGA) are two copolymers made up of three currently FDA approved polymers, used as drug delivery systems for specific indications. Here, the two were investigated to determine how they affected individual blood components and how they affected whole blood. Transmission and scanning electron microscopy imaging for each blood component and whole blood was completed with each amphiphilic copolymer for comparison. It was found that PEG-PLA does not disturb whole blood or its components, but PEG-PLGA harms platelets and plasma. These findings regarding PEG-PLGA show that this material is not compliant with all current FDA standards and could explain why clinical trials are facing complications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · biodegradable polymer synthesis and properties · Advanced Polymer Synthesis and Characterization
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. 10.3390/molecules2404080910.3390/molecules24040809 ↗
2. 10.1002/mabi.20080024810.1002/mabi.200800248 ↗
3. 10.1021/bm801127d10.1021/bm801127d ↗
4. 10.1016/j.jconrel.2011.10.00510.1016/j.jconrel.2011.10.005 ↗
5. 10.1021/acs.biomac.9b0175410.1021/acs.biomac.9b01754 ↗
6. 10.1146/annurev.bioeng.8.061505.09583810.1146/annurev.bioeng.8.061505.095838 ↗
7. 10.1016/j.ejpb.2008.09.02510.1016/j.ejpb.2008.09.025 ↗
8. 10.3389/fphar.2018.0020210.3389/fphar.2018.00202 ↗
9. 10.1016/j.jconrel.2015.12.01510.1016/j.jconrel.2015.12.015 ↗
10. 10.2217/nnm-2017-022110.2217/nnm-2017-0221 ↗
11. 10.2174/13816121179504982210.2174/138161211795049822 ↗
12. U.S. Food and Drug Administration. Development & Approval Process | Drugs, 2019. Available at:https://www.fda.gov/drugs/development-approval-process-drugs#FDA.
13. U.S. Food and Drug Administration. FDA’s Drug Review Process: Continued, 2015. Available at:https://www.fda.gov/drugs/drug-information-consumers/fdas-drug-review-process-continued.
14. U.S. Food and Drug Administration. Recognized Consensus Standards. Medical Device Databases, 2019. Available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/detail.cfm?standard__identification_no=35591. (accessed 24 June 2020).
15. Sall B. · 2013
16. U.S. Food and Drug Administration. The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective, 2017. Available at https://www.fda.gov/drugs/drug-information-consumers/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective%0D.
17. 10.1126/science.284.5417.114310.1126/science.284.5417.1143 ↗
18. 10.1016/S0168-3659(03)00201-310.1016/S0168-3659(03)00201-3 ↗
19. 10.1126/science.107497210.1126/science.1074972 ↗
20. 10.1002/marc.20090058910.1002/marc.200900589 ↗
21. 10.1016/j.jconrel.2017.02.02110.1016/j.jconrel.2017.02.021 ↗
22. 10.3390/pharmaceutics1002005710.3390/pharmaceutics10020057 ↗
23. 10.1016/j.jconrel.2016.06.01710.1016/j.jconrel.2016.06.017 ↗
24. 10.1002/cbin.1045910.1002/cbin.10459 ↗
25. 10.1021/mp800051m10.1021/mp800051m ↗
26. 10.1007/s11095-012-0958-310.1007/s11095-012-0958-3 ↗
27. 10.4155/tde.14.12510.4155/tde.14.125 ↗
28. 10.1038/jcbfm.2012.12610.1038/jcbfm.2012.126 ↗
29. Levesque T.
30. 10.1016/j.jconrel.2006.07.01210.1016/j.jconrel.2006.07.012 ↗
31. 10.1016/j.ijpharm.2017.09.05410.1016/j.ijpharm.2017.09.054 ↗
32. 10.1038/186910.1038/1869 ↗
33. 10.1038/261552a010.1038/261552a0 ↗
34. 10.1182/blood.V32.2.324.32410.1182/blood.V32.2.324.324 ↗
35. Huebsch L. B. · West. J. Med. · 1981 · 134 · 109
36. 10.3109/10731199.2012.66240810.3109/10731199.2012.662408 ↗
37. 10.1557/mrs2010.57110.1557/mrs2010.571 ↗
38. 10.3389/fphar.2018.0126010.3389/fphar.2018.01260 ↗